MyriaScreen Diversity Collection

Sigma-Aldrich

TimTec

Sigma-Aldrich is pleased to announce the availability of the MyriaScreen Diversity Collection of drug-like screening compounds. The collection, produced in collaboration with TimTec Inc., is the result of careful evaluation, filtering, and refinement of selections from each of our screening compound collections. The MyriaScreen Diversity Collection is comprised of 10,000 high-purity screening compounds handpicked to maximize chemical diversity while maintaining drug-likeness.

Superior structural diversity - Distinct drug-like properties

MyriaScreen was created by combining medicinal chemistry expertise and decades of experience in compound acquisition from diverse sources. TimTec’s proprietary software was used to filter a pool of over 300,000 TimTec and Sigma-Aldrich compounds on the basis of diversity. Additional filters were set to consider MW (>225 and <600), cLogP, H-acceptor, H-donors, and rotatable bonds. Medicinal chemistry specialists refined the selection with great personal attention to remove compounds that were overly represented or not well suited for medicinal chemistry follow-up. MyriaScreen is rich in chemotypes and a valuable source of screening compounds for lead discovery.

Ready-to-use format - High purity - Efficient re-supply

MyriaScreen is pre-plated for your convenience, 0.5 mg in 250 µL of DMSO per well. The compounds have an average purity > 95% with nothing below 90%. Should you require more material for follow-up, re-supply or re-synthesis is available. Although MyriaScreen is designed for use as a complete set, there are two alternative options to fit your purchasing needs. Compounds can be purchased as individual plates or cherry-picked and plated on a custom basis.

MyriaScreen was produced in collaboration with TimTec.

Lipinski Rule of Five:

TimTec and Sigma-Aldrich (NASDAQ:SIAL) are pleased to announce the availability of the MyriaScreen Diversity Collection of drug-like screening compounds produced in collaboration, is the result of careful evaluation, filtering, and refinement of selections from each of our screening compound collections.

Sigma-Aldrich Introduces the MyriaScreen Diversity Collection for Drug Discovery Newark, DE, September 23, 2005 –(PR.COM)– TimTec and Sigma-Aldrich (NASDAQ:SIAL) are pleased to announce the availability of the MyriaScreen Diversity Collection of drug-like screening compounds produced in collaboration, is the result of careful evaluation, filtering, and refinement of selections from each of our screening compound collections. MyriaScreen Diversity Collection is comprised of 10,000 high-purity screening compounds handpicked to maximize chemical diversity while maintaining drug-likeness.

MyriaScreen Diversity Collection was assembled from a pool of over 300,000 screening compounds using a combination of filters, diversity predictors, and manual selection. The resulting 10,000 compounds are drug-like, chemically diverse, and amenable to follow-up chemistry and optimization. The collection is well suited for researchers that are looking for a small, cost-effective, ready-to-screen set of high-quality screening compounds. “MyriaScreen will complement our customers’ existing screening collections and jump-start new collections by quickly adding interesting chemotypes,” said Michael Earley, Product Manager, Drug Discovery, Sigma-Aldrich. “Our collaboration with TimTec, Inc. resulted in a high-quality library that our customers will find useful.”

About Sigma-Aldrich

This e-mail address is being protected from spambots. You need JavaScript enabled to view it
http://www.timtec.net